Phenylketonuria Clinical Trial
Official title:
The Early History of Universal Screening for Metabolic Disorders
We are doing this study to learn more about the early history of universal screening for metabolic disorders such as PKU and galactosemia. In particular, we are interested in learning from our past experience to inform our current plans to expand universal newborn screening. Following standard historical research methodology, we will begin with a review of the historical scholarship on PKU and galactosemia, including more general works on mental retardation, genetics, public health screening, and metabolic disorders. We will also obtain scientific publications and archival sources on the early screening and treatment of these disorders. Lastly, we will conduct oral history interviews with key participants in teh early screening and treatment of PKU and galactosemia.
Universal neonatal screening programs for metabolic disorders constitute a triumph of
medicine and public policy in the US over the last 50 years. State programs to identify and
treat disorders such as and galactosemia have saved thousands of lives and prevented serious
morbidity such hypothyroidism, phenylketonuria (PKU), as mental retardation . Advances in
science and technology, including the Human Genome Project, offer the opportunity to expand
universal newborn screening programs to include many new conditions. Although the benefits
of such screening programs appear to outweigh their costs, some critics have pointed to
historical examples that should make us wary of expanding universal newborn screening. For
example, ethicist Norm Fost has stated that early screening programs falsely identified
hundreds of children as having PKU or galactosemia, and that inappropriate treatment of
these children led to death or severe neurodevelopmental impairment . As our nation weighs
the risks and benefits of expanding newborn screening to a variety of metabolic and genetic
conditions, it is critical to revisit the early years of universal screening programs. Did
the extension of screening from at-risk populations to all newborns lead to substantial
morbidity and mortality? If so, what can we learn from our past experience to inform our
current plans to expand universal newborn screening?
We propose to examine the early history of universal screening for PKU and galactosemia in
the US. Following standard historical research methodology, we will begin with a review of
the historical scholarship on PKU and galactosemia, including more general works on mental
retardation, genetics, public health screening, and metabolic disorders. We will also
identify and obtain scientific publications and archival sources that document the early
screening and treatment of these disorders. Lastly, we will conduct oral history interviews
with key participants in the history of early screening and treatment of PKU and
galactosemia. Oral history is a critical component of this project, providing information
not available in any other format. Through oral history interviews, we hope to identify
critical events, key people, and important collateral influencing issues.
The second phase of historical methods requires the scholar to identify key themes based on
the historical record, then present preliminary findings to groups of scholars from a
variety of disciplines. This academic exchange leads the PI to new resources and to refined
key themes. The final phase of historical scholarship is preparation of written conclusions.
As a result of this project, a historical article will be written for a peer-reviewed
journal accessible to clinicians, researchers, and policy experts who are considering how
best to expand universal metabolic screening.
;
Time Perspective: Retrospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05099640 -
A Study of PTC923 in Participants With Phenylketonuria
|
Phase 3 | |
Completed |
NCT01924026 -
Neurocognitive Outcomes in Mild Hyperphenylalaninemia (MHP)MHP Study
|
N/A | |
Completed |
NCT01428258 -
Phase 2 Study of Glycomacropeptide Versus Amino Acid Diet for Management of Phenylketonuria
|
N/A | |
Completed |
NCT00925054 -
Dose-Finding Study to Evaluate the Safety, Efficacy, & Tolerability of Multiple Doses of rAvPAL-PEG in Subjects With PKU
|
Phase 2 | |
Completed |
NCT00778206 -
PKUDOS: Phenylketonuria (PKU) Demographic, Outcomes, and Safety Registry
|
||
Recruiting |
NCT05948020 -
Efficacy and Safety of Orally Administered Engineered Probiotics (CBT102-A) for the Treatment of Children With Phenylketonuria
|
N/A | |
Recruiting |
NCT05781399 -
First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria
|
Phase 1 | |
Completed |
NCT02555579 -
Simplified Diet Approach in Phenylketonuria
|
N/A | |
Completed |
NCT03097250 -
MRI Spectroscopy and Neuropsychological Functioning in Phenylketonuria
|
||
Completed |
NCT01965691 -
Protein Requirements in Children With Phenylketonuria (PKU)
|
N/A | |
Completed |
NCT01965912 -
Kuvan®'s Effect on the Cognition of Children With Phenylketonuria
|
Phase 4 | |
Completed |
NCT00688844 -
Nutritional and Neurotransmitter Changes in PKU Subjects on BH4
|
N/A | |
Completed |
NCT00789568 -
A Phase 1 Study to Evaluate Effects of Sapropterin Dihydrochloride on QTc Intervals in Healthy Adult Subjects
|
Phase 1 | |
Terminated |
NCT01465100 -
Liver Cell Transplant for Phenylketonuria
|
Phase 1/Phase 2 | |
Completed |
NCT01732471 -
Phase 3 Open-label Study to Evaluate the Response and Safety of Kuvan® in Subjects With Phenylketonuria
|
Phase 3 | |
Completed |
NCT04879277 -
Study of Low-grade Systemic Inflammation in Adult Patients With Phenylketonuria
|
N/A | |
Completed |
NCT02176603 -
Observational Study of Endothelial Dysfunction in Phenylketonuria
|
N/A | |
Completed |
NCT01869972 -
Biological Variation of Phenylalanine in Patients With Hyperphenylalaninemia
|
N/A | |
Terminated |
NCT01904708 -
Moderate Intensity Exercise and Phenylketonuria
|
N/A | |
Completed |
NCT01819727 -
An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated w/ BMN 165
|
Phase 3 |